Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 13, 2021 16:55 ET | Source: Processa Pharmaceuticals, Inc.

Processa Pharmaceuticals Announces First Quarter 2021 Results and Provides Corporate Update

Clinical drug pipeline is funded and targeting major milestones in Q2 and 2H 2021 HANOVER, Md., May 13, 2021 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) ("Processa" or the...
May 07, 2021 08:30 ET | Source: Processa Pharmaceuticals, Inc.

Processa Pharmaceuticals Schedules Conference Call to Discuss First Quarter Results and Provide Drug Development Update on May 13 at 5:30 p.m. EST

HANOVER, MD., May 07, 2021 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ: PCSA), (“Processa” or the “Company”), a clinical-stage biopharmaceutical company developing products to improve...
March 25, 2021 16:06 ET | Source: Processa Pharmaceuticals, Inc.

Processa Pharmaceuticals Announces Year end 2020 Results and Provides Corporate Update

Clinical drug pipeline is funded and targeting major milestones in 2021 HANOVER, Md., March 25, 2021 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) ("Processa" or the "Company"),...
March 22, 2021 09:15 ET | Source: Processa Pharmaceuticals, Inc.

Processa Pharmaceuticals Schedules Conference Call to Discuss Fourth Quarter Results and Provide Drug Development Update on March 25 at 5:30 p.m. ET

HANOVER, MD., March 22, 2021 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ: PCSA), (“Processa” or the “Company”), a clinical-stage biopharmaceutical company developing products to...
March 17, 2021 09:15 ET | Source: Processa Pharmaceuticals, Inc.

Processa Announces Sites Selected for Phase 2B Clinical Trial to Treat Patients with Ulcerated Necrobiosis Lipoidica

HANOVER, March 17, 2021 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) ("Processa" or the "Company"), a clinical stage company developing drugs for patients who have unmet medical...
March 02, 2021 09:15 ET | Source: Processa Pharmaceuticals, Inc.

Processa Pharmaceuticals Announces Closing of a $10.2 Million Private Placement

HANOVER, MD, March 02, 2021 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) is pleased to announce it has closed its previously announced private placement to institutional and...
February 17, 2021 08:00 ET | Source: Processa Pharmaceuticals, Inc.

Processa Pharmaceuticals Announces $10.2 Million Strategic Financing

Strengthened Financial Position Supports Execution Through 2023 HANOVER, MD., Feb. 17, 2021 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ: PCSA), (“Processa” or the “Company”), a...
January 11, 2021 10:50 ET | Source: Processa Pharmaceuticals, Inc.

Processa Pharmaceuticals to Present at the H.C. Wainwright BIOCONNECT 2021 Virtual Conference

HANOVER, MD., Jan. 11, 2021 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ: PCSA), (“Processa” or the “Company”), a clinical-stage biopharmaceutical company developing products to...
November 05, 2020 09:15 ET | Source: Processa Pharmaceuticals, Inc.

Processa Pharmaceuticals Announces the Appointment of Dr. Khalid Islam to Its Board of Directors

HANOVER, MD, Nov. 05, 2020 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ: PCSA), (“Processa” or the “Company”), a clinical-stage biopharmaceutical company developing products to improve...
October 13, 2020 09:30 ET | Source: Processa Pharmaceuticals, Inc.

Processa Pharmaceuticals Announces Appointment of Michael Floyd as Chief Operating Officer

HANOVER, Md, Oct. 13, 2020 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ: PCSA) (“Processa” or the “Company”), a clinical-stage biopharmaceutical company developing products to improve...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right